Latest Conference Articles

Acalabrutinib is Better Tolerated, Noninferior to Ibrutinib in Previously Treated CLL

Mirvetuximab Soravtansine Plus Bevacizumab May Provide an Effective Non-Platinum Option in Recurrent, Platinum Agnostic Ovarian Cancer

Mirvetuximab soravtansine in combination with bevacizumab yielded durable responses in patients with recurrent, platinum agnostic ovarian cancer, a population in need of more effective, non-platinum treatments.

Larotrectinib Demonstrates Promising Responses in NTRK-Fusion+ CNS Tumors

Larotrectinib has demonstrated efficacious responses and disease control in patients with TRK fusion–positive central nervous system tumors.

Insights in Breast Cancer, GI Malignancies at ASCO 2021: Drs Milind Javle and Erika Hamilton

Lenvatinib/Pembrolizumab Yields Continuing Efficacy in Advanced Melanoma

Lenvatinib and pembrolizumab continued to yield meaningful and durable responses in patients with advanced melanoma who had progressed on previous PD-L1 inhibitor treatment.

Lifileucel Continues to Demonstrate Durable Responses in Heavily Pretreated Advanced or Metastatic Melanoma

Lifileucel has demonstrated promising long-term responses in patients with heavily pretreated advanced or metastatic melanoma who have progressed following PD-1 and PD-L1 inhibition.

Nivolumab Alone, With Ipilimumab Maintains Improved Outcomes in Advanced Melanoma in Long-Term Follow-Up

Nivolumab monotherapy, or in combination with ipilimumab, continued to demonstrate durable improvements in overall survival compared with ipilimumab alone in patients with previously untreated advanced melanoma.

Selpercatinib Elicits Encouraging Antitumor Activity in Pediatric RET-Altered Solid Tumors

Selpercatinib demonstrated evidence of preliminary efficacy and safety in pediatric patients with advanced RET-altered solid tumors.

Selpercatinib Improves Responses Regardless of Immediate Prior Treatment in RET-Mutant Medullary Thyroid Cancer

Selpercatinib improved overall response rates in most patients with RET-mutated medullary thyroid cancer irrespective of prior systemic therapy.

Nivolumab Plus Chemotherapy Outperforms Chemotherapy Alone in Resectable NSCLC

Neoadjuvant nivolumab in combination with platinum-doublet chemotherapy significantly improved pathological complete response rates and had a greater depth of pathological response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

Adjuvant Gefitinib Fails to Outshine Chemo in EGFR+ NSCLC

Adjuvant treatment with gefitinib delayed early relapse in patients with completely resected EGFR-mutant non–small cell lung cancer. However, the EGFR inhibitor did not significantly improve disease-free survival or overall survival compared with cisplatin/vinorelbine.

Ultralow Risk 70-Gene Signature Is Indicative of Excellent Survival Outcomes in Early-Stage Breast Cancer

Patients with early-stage breast cancer who have ultralow risk disease indicated by a 70-gene signature demonstrated have an excellent survival prognosis regardless of clinical risk.

Neoadjuvant Pyrotinib Quadruplet Significantly Improves pCR in HER2+ Breast Cancer

The combination of pyrotinib plus trastuzumab, docetaxel, and carboplatin (TCbH) significantly improved the total pathological complete response rate over TCbH alone in the neoadjuvant treatment of patients with HER2-positive breast cancer.

Neoadjuvant Pertuzumab Plus Trastuzumab/Nab-Paclitaxel Achieves 64% pCR With Less Toxicity in HER2+ Breast Cancer

Pertuzumab plus trastuzumab, and nab-paclitaxel used as neoadjuvant therapy in patients with HER2-positive locally advanced breast cancer induced a pathologic complete response similar to that achieved with docetaxel, carboplatin, trastuzumab, and pertuzumab, with less treatment-related toxicities.

CART-ddBCMA Elicits 100% ORR in Relapsed/Refractory Multiple Myeloma

The autologous CAR T-cell product CART-ddBCMA was found to elicit a 100% objective response rate in patients with relapsed/refractory multiple myeloma, with deep and durable responses noted in those with poor prognostic factors.

Meaningful Impact on Outcomes Demonstrated with De-Escalation Strategy in HER2+/HR– Breast Cancer

A de-escalated course of neoadjuvant therapy of trastuzumab and pertuzumab with or without added weekly paclitaxel for only 12 weeks yielded high response rates and significant survival in patients with HER2-positive, hormone receptor–negative early breast cancer.

Durvalumab Plus Neoadjuvant Chemotherapy Yields Long-Lasting Survival in Early TNBC

The addition of durvalumab to neoadjuvant anthracycline and taxane–based chemotherapy was found to significantly improve survival in patients with early triple-negative breast cancer.

Improved Responses Sustained With Pembrolizumab in Treatment-Naïve Melanoma, But Not in Rechallenged Patients

Patients with stage III melanoma who progressed following placebo-based treatment in the first part of the phase 3 EORTC 1325/KEYNOTE-054 trial and crossed over to receive pembrolizumab post-recurrence derived a 38.8% overall response rate and a 32% overall 3-year progression-free survival rate.

Dr. Tawbi on the Efficacy of Relatlimab/Nivolumab in Advanced Melanoma

Hussein A. Tawbi, MD, PhD, discusses the efficacy of relatlimab plus nivolumab in patients with advanced melanoma.

Targeting CLL1-Positive Cells Shows Efficacy in Early Trial in Pediatric AML

Investigators validated the safety and efficacy of anti-C-type lectin-like molecule-1-based CAR T cells in a small clinical trial of pediatric patients with relapsed/refractory acute myeloid leukemia.

Tafasitamab/Lenalidomide Combo Induces Durable Response in DLBCL

Three-year follow-up data from the phase 2 L-MIND study demonstrated that tafasitamab-cxix in combination with lenalidomide induces sustainable response in relapsed/refractory diffuse large B-cell lymphoma.

Lung Cancer and Leukemia Recap at ASCO 2021: Drs Ed Kim and Anthony Mato

Selumetinib Response Not Driven by MAPK Expression in Pediatric and AYA Refractory Solid Tumors

Selumetinib did not elicit clinical activity in pediatric and young adult patients with refractory cancers who had actionable mutations in the RAS/RAF/MAPK1/2-ERK pathway.

Liposomal Irinotecan Combo Improves Outcomes for Patients with Biliary Tract Cancer

Data from the phase 2 NIFTY trial demonstrated that liposomal irinotecan in combination with 5-fluorouracil/leucovorin significantly improved progression-free survival and overall survival for patients with metastatic biliary tract cancer whose disease had progressed following first-line line gemcitabine/cisplatin.

Ribociclib/Fulvestrant Maintains Survival Benefit in Postmenopausal HR+ Advanced Breast Cancer, Irrespective of Setting

Ribociclib plus fulvestrant continued to significantly improve overall survival over fulvestrant alone in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer at almost 5 years of follow-up, irrespective of whether patients received the regimen in the first- or second-line setting.

Frontline Camrelizumab Plus Chemotherapy Improves Survival in Advanced Esophageal Squamous Cell Carcinoma

Camrelizumab in combination with chemotherapy demonstrated improved overall survival and progression-free survival and a manageable safety profile as frontline therapy compared with placebo plus chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma.

Venetoclax/Fulvestrant Combo Found to Be Inferior to Fulvestrant Alone in ER+/HER2- Breast Cancer

The combination of venetoclax and fulvestrant failed to improve overall outcomes vs fulvestrant alone in patients with locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer who had previously received a CDK4/6 inhibitor.

Palbociclib/Fulvestrant Combo Maintains OS Benefit in HR+ Breast Cancer

At a median follow-up of 73.3 months, investigators in the PALOMA-3 trial have concluded that palbociclib plus fulvestrant maintains a clinically meaningful improvement in overall survival compared with placebo plus fulvestrant for patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Slamon on the Benefit of Ribociclib Plus Fulvestrant in HR+/HER2- Advanced Breast Cancer

Dennis J. Slamon, MD, PhD, discusses the long-term benefit of ribociclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Alectinib Fails to Improve OS in ALK-Positive NSCLC

In a final overall survival analysis of the J-ALEX study, patients with non-small cell lung cancer receiving alectinib failed to achieve better results than patients receiving crizotinib.